19Oct

Demystify Chromogenic Factor VIII Testing’

For laboratories wishing to accurately quantify Factor VIII activity, there is now a ready-to-use Chromogenic Factor VIII Assay. The CRYOcheck™ assay is designed for ease of use and to minimise reagent waste. The assay is intended to identify Factor VIII deficiency and aid in the management of haemophilia A.

Available in the UK exclusively from Alpha Laboratories, the new kit developed by Precision BioLogic offers a validated protocol.

CRYOcheck Chromogenic Factor VIII is the only chromogenic assay offered in a frozen format.  The vials are simply thawed in a standard water bath, loaded onto an automated coagulation analyser, and they ready to go!  With only four separate components, provided in convenient colour coded vials, running the assay is very straight forward. 

The CRYOcheck Chromogenic Factor VIII assay is suitable for both high and low volumes of testing. It can be scaled up in the lab for high volume testing, and the ability to store unused reagents refrigerated for up to 5 days, or frozen for up to 1 month, makes the kit perfect for low volume testing too. The kit offers total flexibility in Factor VIII activity testing.

The Assay will save you time, improve your workflow and eliminate reconstitution errors.  The CRYOcheck Chromogenic Factor VIII Assay provides unsurpassed assurance in results.

Please visit www.alphalabs.co.uk/cccf08 for further information or contact Alpha Laboratories on 0800 38 77 32 or email marketing@alphalabs.co.uk   

Related

New AbC-19™ COVID-19 antibody test developed by Abingdon Health and the UK-RTC

As demand for rapid testing continues to accelerate at an unprecedented level, our response to assis...

Read More >

OGT unveils reliable somatic CNV detection for CLL with new NGS panel

SureSeq™ CLL + CNV - comprehensive CLL genomic profiling from a single assay

Read More >

OGT continues move into molecular diagnostics markets with MDSAP certification

Certification of new Cambridge facility smooths path to future IVD approvals

Read More >

OGT further expands global direct sales and support into Asia-Pacific region

Following successful European rollout, more customers to benefit from enhanced local sales and suppo...

Read More >

In Brief This Week: VolitionRx, Bio-Techne, Biocept, Meridian Bioscience, and More

NEW YORK (360Dx) – VolitionRx reported a second quarter net loss of $3.5 million, or $.13 per share...

Read More >